Fig. 1: Eliglustat mediates tumour growth inhibition through the host immune system in vivo. | Nature Communications

Fig. 1: Eliglustat mediates tumour growth inhibition through the host immune system in vivo.

From: Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial

Fig. 1

a Experimental design. A total of 1 × 105 tumour cells were subcutaneously injected and observed for tumour formation in C57BL/6 mice treated with different doses of eliglustat. b C57BL/6 mice were implanted with 1 × 105 MC38-OVA tumour cells, and the treatment scheme is shown in (a). Tumour sizes were measured every 3 days. The average and individual tumour curves (n = 10 per group) are shown. c Survival curves of MC38-OVA tumour-bearing mice in the control and 10 mg/kg eliglustat-treated groups (n = 10 per group). d Body weights of MC38-OVA tumour-bearing mice in the control and 10 mg/kg eliglustat-treated groups (n = 10 per group). e Injection schedule for antibody-mediated depletion of CD4+ and CD8+ T cells and NK cells and eliglustat treatment in MC38-OVA tumour-bearing mice. f C57BL/6 mice were implanted with 1 × 105 MC38-OVA cells, as shown in (e). Tumour sizes were measured every 3 days. The average and individual tumour curves (n = 7 per group) are shown. The data are shown as the mean ± SEM. ns, not significant. P values were calculated by unpaired two-sided t test in (d). P values were calculated by two-way repeated measures analysis of variance (ANOVA) in (b) and (f) and the log-rank test in (c). CON control, ELI eliglustst. Source data and exact p values are provided as a Source Data file.

Back to article page